On 29th, March, Hasten Biopharmaceutical Co., Ltd (hereinafter referred to as "Hasten") signed a strategic cooperation agreement with Naxions on the "Hasten&Naxions Innovation Project". According to the agreement, Naxions will assist in promoting the accessibility of Hasten's high-quality products in specific markets through its multi-dimensional digital model to benefit more patients and jointly create greater social health value.

On December 19, 2023, Hasten’s CEO Summer XIA, Vice President and Head of Commercial Excellence Hanson Zheng and other senior leaders from Hasten visited Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun), and signed a MOU for the deep collaboration with CR Gosun.

On December 14, 2023, Hasten Biopharmaceutical Co., Ltd announced that it will enter into a strategic business partnership with Apeloa Pharmaceutical Co., Ltd.

December 8th, 2023 – Shanghai, China. Avon Group, a leading global professional services firm, today announced it has released the China Best ESG Employers Award list for 2023 and another eight earning individual awards for outstanding performance in their specific fields. Hasten Biopharmaceutical Company Limited (Hasten) was awarded " 2023 China's Best Employer ESG Seed Award" for the energy and great potential of company’s organizational optimization and agile operation model.

Hasten Biopharmaceutical Co., Ltd. (Hasten) and China Resources Pharmaceutical Commercial Group (Shanghai) Co., Ltd. reached a strategic cooperation at the 6th CIIE on November 7th of 2023.

近日，海森生物醫(yī)藥有限公司獲悉有不法分子假冒我司名義發(fā)布招聘信息、邀請面試以及給求職人員發(fā)送虛假錄用通知函等行為，嚴(yán)重侵害了我司和廣大應(yīng)聘者的合法權(quán)益。為防止應(yīng)聘者的切身利益受到損害，維護(hù)我司的聲譽(yù)，我公司現(xiàn)鄭重聲明如下：